Integrin Targeted Delivery of Chemotherapeutics by Chen, Kai & Chen, Xiaoyuan





T Th he er ra an no os st ti ic cs s   
2011; 1:189-200 
Review 
Integrin Targeted Delivery of Chemotherapeutics 
Kai Chen 1,2  and Xiaoyuan Chen 1  
1.  National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD;  
2.  Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los 
Angeles, CA  
 Corresponding author: Dr. Xiaoyuan Chen, Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National 
Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), 31 Center Dr, 31/1C22, 
Bethesda, MD 20892, USA; Tel: 301-451-4246; Email: shawn.chen@nih.gov; Dr. Kai Chen, Molecular Imaging Center, De-
partment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Tel: 
323-442-3582; Email: chenkai@usc.edu 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Published: 2011.02.17 
Abstract 
Targeted delivery of chemotherapeutics is defined in the sense, that is, to maximize the 
therapeutic index of a chemotherapeutic agent by strictly localizing its pharmacological ac-
tivity to the site or tissue of action. Integrins are a family of heterodimeric transmembrane 
glycoproteins involved in a wide range of cell-to-extracellular matrix (ECM) and cell-to-cell 
interactions. As cell surface receptors, integrins readily interact with extracellular ligands and 
play a vital role in angiogenesis, leukocytes function and tumor development, which sets up 
integrins as an excellent target for chemotherapy treatment. The peptide ligands containing 
the arginine-glycine-aspartic acid (RGD), which displays a strong binding affinity and selectivity 
to integrins, particularly to integrin αvβ3, have been developed to conjugate with various 
conventional chemotherapeutic agents, such as small molecules, peptides and proteins, and 
nanoparticle-carried drugs for integtrin targeted therapeutic studies. This review highlights 
the recent advances in integrin targeted delivery of chemotherapeutic agents with emphasis 
on target of integrin αvβ3, and describes the considerations for the design of the diverse RGD 
peptide-chemotherapeutics conjugates and their major applications. 
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Introduction 
Chemotherapy has been the main approach for 
the  systemic  treatment  of  advanced  or  metastatic 
diseases for more than half century. During the cells 
division  process,  chemotherapeutics  is  capable  of 
killing  proliferating  cells,  hence  affecting  aberrant 
cells.  While  highly  efficient  in  preventing  disease 
progression, however, chemo-therapeutic agents are 
often lack of selectivity for aberrant cells. Their tox-
icity to normal cells and non-diseased tissues, espe-
cially  to  rapidly  growing  cells  such  as  blood,  bone 
marrow and mucous membrane cells, cause serious 
side-effects  that  impose  to  administrate  the  chemo-
therapeutic agents at sub-optimal doses [1]. Because 
of  intrinsic  or  acquired  resistance  of  aberrant  cells, 
benefits of the chemotherapeutic agents are also often 
limited [2]. The efficiency of the treatment can be in-
creased by escalating the doses, but this option com-
monly  results  in  considerable  toxicity  problem  and 
thus  is  rarely  considered.  Selective  delivery  of 
chemotherapeutic agents to the disease site therefore 
represents  a  major  challenge  for  improving  current 




chemotherapeutics  is  an  emerging  therapy  strategy 
endowed with disease-targeting functions and carry-
ing  cytotoxic  components  by  enabling  the  specific 
delivery of chemotherapeutic agents to aberrant tis-
sues, thereby increasing their local efficacy while lim-
iting their peripheral toxicity. Clearly, the success of 
this approach is heavily on the rational selection of 
appropriate biological targets.  
Integrin – An ideal therapeutic target 
In the past two decades, many efforts have been 
made  to  the  discovery  of  cell  adhesion  molecules 
(CAMs), and their distinctive functions in cell mor-
phology,  locomotion,  mitosis,  cytokinesis,  phagocy-
tosis, and the maintenance of cell polarity [4-6]. It is 
known  that  CAMs  play  important  roles  in  various 
disease states such as cancer [7-9], thrombosis [10-11], 
rheumatoid arthritis [12], and diabetes [13]. Numer-
ous studies have been actively performing in investi-
gation  of  the  structure,  function,  and  recycling 
mechanisms of some CAMs, as well as how to mod-
ulate  them  for  controlling  disease  progression  [14]. 
CAMs are glycoproteins expressed on the cell surface 
that  functionalize  as  receptors  for  cell-to-cell  and 
cell-to-extracellular matrix (ECM) adhesion [15-17]. In 
general, CAMs can be divided into four classes: in-
tegrins, selectins, cadherins, and the immunoglobulin 
superfamily.  
Among  these  CAMs,  integrins  are  a  family  of 
heterodimeric  transmembrane  glycoproteins  involv-
ing  in  a  wide  range  of  cell-to-ECM  and  cell-to-cell 
interactions [18-19]. Each member of this family con-
sists  of  non-covalently  bound  transmembrane  poly-
peptide α and β subunits. In mammals, 18 α and 8 β 
subunits have been identified, which assemble into at 
least 24 different integrins [20]. The term integrin is 
derived from the ability of these proteins to link the 
ECM proteins with the intracellular cytoskeleton [21]. 
During  binding  to  ECM  proteins,  integrins  form 
clusters at the cell membrane that are associated with 
a cytoskeletal complex to promote actin filament as-
sembly  [22-23].  In  turn,  the  reorganization  of  actin 
filaments  into  large  stress  fibers  increases  integrin 
clustering followed by enhancement of binding affin-
ity  with  ECM  proteins  [24].  During  cell  locomotion 
and migration, integrin can undergo endocytosis and 
exocytosis [25-27]. In the process of cell locomotion, 
integrins activation can be triggered by vascular en-
dothelial  growth  factor  (VEGF)  and  controlled  by 
protein  kinase  C  (PKC)  to  continuously  form  new 
integrin-based  focal  contacts  at  the  front  of  the  cell 
[28]. While the cell migrates, the integrin interaction is 
released from extracellular ligands at the rear of the 
cells after forming new and persistent integrin con-
nections at the front of the cell [29-30]. In migrating 
neutrophils,  the  distribution  of  integrins  was  ob-
served to be maintained by Ca2+-dependent release of 
cell adhesion followed by endocytosis of the integrin 
[31]. Thus, integrin endocytosis has been considered 
as  an  attractive  mechanism  for  controlling  cell  sig-
naling pathways which can be stimulated by ligand 
binding. 
The characteristic that integrins can be internal-
ized  by  cells  on  activation  with  anchoring  ligands 
significantly facilitates delivery of chemotherapeutics 
into  neoplastic  cells  and  leukocytes,  while  these 
chemotherapeutics  conjugate  with  integrin-targeted 
ligands. Additionally, integrins are over-expressed on 
angiogenetic  endothelial  cells,  whereas  they  are  ab-
sent in pre-existing endothelial cells and normal tis-
sues. Moreover, it has been found that certain tumor 
cells  over-express  integrins  on  their  cellular  mem-
brane surface [32-34], which makes selective delivery 
of  chemotherapeutic  agents  possible.  All  of  these 
characteristics set up integrin an ideal target for both 
cancer and anti-angiogenesis therapy.  
Integrin and RGD-peptide  
The  arginine-glycine-aspartic  acid  (RGD)  cell 
adhesion sequence was discovered in fibronectin over 
two decades ago [35-36]. Later on, RGD-recognition 
sites were found in other ECM proteins [37-40] and 
the receptors for these ECM proteins were identified 
in the integrin family. Proteins that contain the RGD 
attachment site, together with the integrins that serve 
as receptors for them, constitute a major recognition 
system for cell adhesion. The RGD sequence is the cell 
attachment site of a number of adhesive ECM, blood, 
and cell surface proteins. It has been found that nearly 
half of the over 20 known integrins, including all five 
αv integrins, two β1 integrins (α5, α8) and αIIbβ3 in-
tegrin, recognize this sequence in their adhesion pro-
tein ligands [41].  
The  integrin  αvβ3,  consisting  a  125-kDa  αv 
subunit and a 105-kDa β3 subunit, binds a wide range 
of ECM proteins with RGD-containing components of 
the interstitial matrix such as vitronectin, fibronectin 
and  thrombospondin  [42-43].  Crystal  structures  of 
integrin αvβ3 complexed with RGD ligands have re-
vealed an atomic basis for this interaction [43]. RGD 
binds at an interface between the α and β subunits, the 
R residue fitting into a cleft in a β-propeller module in 
the subunit, and the D coordinating a cation bound in 
a von Willebrand factor A - domain in the β subunit. It 
is well documented that Integrin αvβ3 is expressed on 
the cell membrane of various tumor cell types such as 
late  stage  glioblastoma,  melanoma,  ovarian,  breast, 




critical role in tumor invasion and metastasis arising 
from  its  ability  to  recruit  and  activate  MMP-2  and 
plasmin,  which  can  degrade  components  of  the 
basement  membrane  and  interstitial  matrix  [44]. 
Among  integrins  family,  integrin  αvβ3  is  the  most 
intensively  studied  although  many  other  integrins 
such  as  αvβ1,  αvβ5,  α5β1,  and  α4β1  also  play  im-
portant roles in regulating angiogenesis [45-49]. 
Based on these findings, linear as well as cyclic 
RGD peptides have been developed as ligands that 
preferentially bind to integrin αvβ3, related αv integ-
rins, or other types of integrins. Among these RGD 
peptides,  cyclic  peptides  c(RGDfK)  and  c(RGDyK), 
RGD4C, and RGD10 (Figure 1) showed high binding 
affinity and selectivity for integrin  αvβ3 [50]. Thus, 
these RGD-peptides can be served as vectors for in-
tegrin αvβ3 targeted delivery of chemotherapeutics. 
Cyclic peptides c(RGDfK) and c(RGDyK) are the ones 
mostly  used  for  the  delivery  of  therapeutic  agents. 
The amino group of the lysine residue on these pep-
tides is an ideal site for further chemical conjugation 
reactions. Multivalent c(RGDfK) or c(RGDyK) peptide 
can be used to achieve higher binding affinity. Both of 
RGD4C  and  RGD10  peptide  were  discovered  by 
phage display technology  [51-52]. The RGD4C pep-
tide contains two disulfide bonds and displays at least 
20-fold more potent than similar peptide with a single 
disulfide bond. Although the RGD10 peptide contains 
only  one  disulfide  bond,  the  residues  flanking  the 
CRGDC core display similar physicochemical prop-
erties as those in RGD4C. Overall, RGD4C and RGD10 
show similar binding affinity to integrin αvβ3.   
To date, agents that are commonly used to con-
jugate  with  RGD-peptides  for  chemotherapy  treat-
ments are: a) therapeutic  small  molecules, b)  thera-
peutic  peptides  and  proteins,  and  c)  nanoparti-
cle-carried chemotherapeutics.  
 
 
Fig. 1 Chemical Structures of c(RGDyK), c(RGDfK), [c(RGDyK)2], RGD4C, and RGD10. Due to high binding affinity for 





Integrin targeted delivery of therapeutic 
small molecules  
The first approach in which the RGD-peptide is 
used for drug targeting purposes focuses on the de-
livery of cytotoxic drugs for cancer treatments. These 
treatments  are  often  effective,  however,  their  high 
toxicity  to  healthy  tissues  is  difficult  to  tolerate  for 
patients. Thus, development of alternative vectoriza-
tion  of  the  cytotoxic  drugs  without  killing  healthy 
cells  is  critically  demanded  to  circumvent  this  side 
effect.  
For instance, doxorubicin, commonly used anti-
cancer drug, was conjugated with RGD-peptides for 
integrin  targeted  therapy.  A  doxorubicin-RGD4C 
conjugate  (doxo-RGD4C)  is  one  of  good  examples. 
Doxo-RGD4C  demonstrated  equal  efficacy  as  free 
doxorubicin  in  vitro  and,  more  importantly, 
doxo-RGD4C showed improved inhibition of tumor 
growth and spreading of pulmonary metastases than 
free doxorubicin in mouse MDA-MB-435 breast can-
cer model, in which integrin αvβ3 is expressed by the 
endothelium in the angiogenic blood vessels and by 
the  tumor  cells  themselves  [53].  In  addition, 
doxo-RGD4C was also found to be less toxic to liver 
and heart. In another similar study, doxo-RGD4C was 
tested  in  mouse  αvβ3-negative  MH134  hepatoma 
tumor model. As compared to doxorubicin alone, the 
doxo-RGD4C  conjugate  showed  less  treatment  effi-
cacy  in  vitro;  however,  the  doxo-RGC4C  conjugate 
demonstrated  better  anti-tumor  activity  in vivo.  Be-
cause  direct  anti-tumor  cell  effects  of  the  targeted 
doxorubicin  are  not  expected  in  this  integrin 
αvβ3-negative tumor model, this study suggests the 
anti-angiogenetic  effect  on  the  endothelial  cells  in-
duced by doxo-RGD4C conjugate may lead to tumor 
recession [54].  
One of the current strategies for providing sub-
stantial  increases  in  the  clinical  efficacy  of  chemo-
therapeutic  agents  that  preferentially  kill  dividing 
cells, both normal and tumor, is the use of relatively 
nontoxic prodrug forms that can be selectively acti-
vated in aberrant tissue [55]. Prodrugs are generally 
defined as agents that are transformed after admin-
istration, either by metabolism or spontaneous chem-
ical breakdown, to pharmacologically active species. 
Several doxo-RGD4C conjugates have been designed 
as integrin αvβ3 targeted prodrugs that require acti-
vation  by  tumor-secreted  enzymes.  This  strategy 
would reduce the toxicity of drugs and allow higher 
doses to be systemically delivered than non-targeted 
chemotherapeutic  agents.  A  prodrug  containing  a 
plasmin-specific  cleavage  site  was  developed  by  de 
Groot et al. [56]. The release of the parent drug - dox-
orubicin  can  be  achieved  by  plasmin  cleavage  fol-
lowed by accumulation of the prodrug onto integrin 
αvβ3. In vitro studies showed the promising activity of 
prodrug  after  incubation  with  plasmin.  The 
RGD-doxo prodrug was further proved to be capable 
of  blocking  the  adhesion  of  endothelial  cells  to  vit-
ronectin in submicromolar concentrations, suggesting 
the  prodrug  retained  antiangiogenic  activity.  How-
ever, poor solubility of doxo-RGD4C prodrug as well 
as difficulty of synthesizing RGD4C-drug conjugates 
are problematic for further development of this type 
of agents [54, 56-57]. In addition, two disulfide bonds 
in the RGD4C peptide are susceptible to be disrupted 
under  reduced  condition  in  cytoplasm,  resulting  in 
inactive form. In a recent study, Burkhart et al. [57] 
designed  two  RGD-based  (RGD4C  and  Cilengitide) 
conjugates  with  the  doxsaliform  prodrug,  which  is 
spontaneously converted into an active metabolite of 
doxorubicin, doxorubicinformaldehyde, and leads to 
more cytotoxicity than doxorubicin [58]. Both conju-
gates maintained high affinity to integrin αvβ3 with 
IC50 values of 5-10 nanomolar. The in vitro cytotoxicity 
studies  also  revealed  good  growth  inhibition  of 
MDA-MB-435 breast cancer cells, demonstrating their 
capability  of  binding  to  integrin  αvβ3.  Further  ex-
periments showed that the RGD-containing prodrugs 
cannot significantly penetrate the cell membrane, in 
contrast to native doxorubicin and the released dox-
orubicin-formaldehyde.  Thus,  the  proposed  mecha-
nism of action of these conjugates is to bind to integrin 
αvβ3 initially, followed by local release of the more 
lipophilic  doxorubicin  species,  which  then  diffuse 
through  cell  membranes.  Unfortunately,  this  study 
only focused on in vitro stage. In vivo anti-tumor effi-
cacy of these two conjugates was not reported.   
Besides doxorubicin, several other chemothera-
peutic  small  molecules  were  also  conjugated  with 
RGD-peptides. We recently evaluated the antitumor 
activity of paclitaxel conjugated with a dimeric RGD 
peptide E[c(RGDyK)]2 (RGD2) [59]. Paclitaxel (PTX), 
a prototype of the taxane family of antitumor drugs, is 
commonly used in the treatment of advanced meta-
static breast cancer. The RGD2-PTX conjugate inhib-
ited cell proliferation with activity in comparable with 
that observed for paclitaxel, both of which are medi-
ated by an arrest of G2/M phase of the cell cycle fol-
lowed by apoptosis. We then labeled RGD2-PTX with 
125I through the tyrosine residue on the RGD peptide. 
Integrin-specific  accumulation  of  125I-RGD2-PTX  in 
orthotopic  MDA-MB-435  tumor  was  observed.  In  a 
follow-up study, we evaluated the in vivo anti-tumor 




efficacy of RGD2-PTX was confirmed by size meas-
urement,  in  vivo  PET  imaging,  and  ex  vivo  histo-
pathology. The tumor growth delay is related to tu-
mor  proliferation  rather  than  tumor  metabolism,  as 
confirmed by [18F]FDG and [18F]FLT PET imaging. 
Kok’s group recently developed a novel linking 
technique for the conjugation of drug to carriers by 
applying  platinum-coordination  chemistry  [61].  The 
so-called universal linker system (ULS) can release the 
drug  via  a  slow  release  profile.  Thus,  a  prolonged 
action  of  the  delivered  drug  can  be  achieved.  New 
classes  of  drug  carriers  consisted  human  serum  al-
bumin (HSA), cyclic RGD peptides, and polyethylene 
glycol (PEG). A kinase inhibitor PTK787 binds to the 
ULS  through  a  coordination  linkage  at  one  of  the 
aromatic  nitrogen  atoms.  Drug-targeting  conjugates 
and the respective control conjugates were analyzed 
for binding affinity to the integrin αvβ3 target recep-
tor  on  human  umbilical  vein  endothelial  cells 
(HUVEC).  All  RGD-equipped  conjugates  displayed 
reasonable  binding  affinity  to  integrin  αvβ3,  sug-
gesting  the  conjugated  PTK787  did  not  obstruct 
binding  of  the  RGD-modified  carriers  to  integrin 
αvβ3. The highest binding affinity was observed for 
RGD-PTK787-HSA  (IC50  =  4.4  nM)  followed  by 
RGD-PTK787-HSA-PEG  (IC50  =  65  nM)  and 
RGD-PEG-PTK787-HSA (IC50 =  640 nM). The result 
implies the additional incorporation of PEG partially 
obstructed binding in vitro; however, in vivo effect of 
the PEG moiety for these particular conjugates keeps 
unknown.  Kok’s  group  also  developed  a  series  of 
closely related drug targeting conjugates, consisting 
of albumins equipped with RGD-peptide, PEG stealth 
domains, and either the antitubulin agent monome-
thyl auristatin E (MMAE) or a new F-variant (MMAF) 
[62-63].  Since  MMAF  has  a  C-terminal  charge,  this 
compound is potentially less prone to passive redis-
tribution after its release from the carrier. The results 
demonstrated  that  RGD-equipped  albumin  conju-
gates  with  MMAF  were  more  potent  than  MMAE 
conjugates, in killing both integrin αvβ3-positive tu-
mor cells and proliferating endothelial cells. Efficacy 
increased more in tumor cells than in endothelial cells, 
suggesting different drug redistribution behavior for 
the two cell types. However, in vivo studies need to be 
performed  to  further  evaluate  in  vivo  efficacy  and 
toxicity of these RGD-drug conjugates. 
The  various  conjugates  of  RGD-peptides  and 
therapeutic small molecules [53-54,56,57,59,61-66] are 
summarized in Table 1.  
 
Table 1 Integrin targeted delivery of therapeutic small molecules 
Therapeutic agent  Targeting motif  Experimental model  Resultsa  Ref. 
In Vitro  In Vivo 
Doxorubicin (Dox)  RGD4C  MDA-MB-435 mammary carcinoma  +  +  [53] 
Doxorubicin  RGD4C  MH134 murine hepatoma  –  +  [54] 
Plasmin cleavable prodrug   RGD4C  HUVEC  =  ND  [56] 
Doxsaliform (doxorubicinformaldehyde)  c[RGDf(N-Me)V]  MDA-MB-435  =  ND  [57] 
Doxorubicin  RGD-containing tetrameric 
peptide 
H2009 and H1299  +  ND  [64] 
Paclitaxel  [c(RGDyK)]2  MDA-MB-435  +  ND  [59] 
Arabinoside C  RGDSK  B16 melanoma  –  =  [66] 
PTK787 albumin  c(RGDfK)-PEG  HUVEC  +  ND  [61] 
MMAE (Auristatin E)  c(RGDfK)-PEG  C26 murine colon carcinoma  +  +  [65] 
MMAF (Auristatin F)  c(RGDfK)-PEG  C26 murine colon carcinoma  +  ND  [62] 
SB202190 (the p38 MAPkinase Inhibitor)  c(RGDfK)-PEG  HUVEC  +  ND  [63] 




Integrin targeted delivery of therapeutic 
peptide and proteins  
The second approach relies on the conjugation of 
integrin ligands with therapeutic biologically relevant 
biomolecules, such as peptides and proteins, to target 
them  to  the  specific  site  for  their  action.  A  good 
number of therapeutic peptides and proteins are cur-
rently becoming available for the treatment of cancer 
and other diseases. However, poor pharmacokinetics 
and  unacceptable  side-effects  are  often  limiting  the 
efficacy of these biomolecules. For instance, cytokines 
show  potent  activity  in  various  cancers,  but  they 
normally display a range of other actions within the 
body,  which  may  cause  severe  adverse  events. 
Cell-specific targeting of a cytokine may significantly 
improve its selectivity for the target cells within the 
tumor and, thus, enhance its efficacy. In general, bi-
omolecules,  such  as  therapeutic  peptides  and  pro-
teins,  are  hydrophilic  and  they  have  short  plasma 
half-life.  In  order  to  achieve  favorable  pharmacoki-
netic  properties  of  therapeutic  biomolecules,  struc-
tural  optimizations  of  RGD-peptides  by  using 




could potentially prevent fast renal clearance, enzy-
matic  degradation  of  the  biomolecules,  and  extend 
therapeutic windows.     
The  conjugate  of  RGD4C  peptide  with  a 
pro-apoptotic cationic peptide (KLAKLAK)2 has been 
reported  [67].  The  in  vitro  results  showed 
RGD4C-(KLAKLAK)2  induced  apoptosis  in  Kaposi 
sarcoma  tumor  cells.  In  vivo  studies, 
RGD4C-(KLAKLAK)2 reduced tumor weight and size 
as well as diminish the formation of lung metastases. 
In  addition,  intravenous  administration  of 
RGD4C-(KLAKLAK)2  to  mice  subjected  to  colla-
gen-induced  arthritis  significantly  reduced  the  ar-
thritic score [68], which is attributed by apoptosis of 
endothelial cells in the inflamed synovium. This study 
demonstrated that targeting to integrin αvβ3-positive 
endothelial cells is not only limited to the treatment of 
cancer, but also can be a feasible therapeutic approach 
for  chronic  inflammatory  disease,  in  which  angio-
genesis is a hallmark of disease progression as well. In 
another study [69], RGD4C peptide was conjugated 
with a naturally occurring antimicrobial cationic pep-
tide,  tachyplesin.  The  in  vitro  results  showed  that 
RGD4C-tachyplesin inhibited the proliferation of both 
cultured tumor and endothelial cells and reduced the 
colony formation of TSU prostate cancer cells. The in 
vivo  studies  indicated  that  the  RGD4C-tachyplesin 
could  inhibit  the  growth  of  tumors  on  the  chori-
oallantoic  membranes  of  chicken  embryos  and  in 
syngeneic mice. 
Tumor  necrosis  factor  α  (TNF-α)  is  a  mul-
ti-functional cytokine playing a key role in apoptosis 
and cell survival, as well as in inflammation and im-
munity.  Although  TNF-α  treatment  on  tumor  pro-
gression  shows  beneficial  effects  in  animal  studies, 
clinical use of TNF-α in treatment of cancer is limited 
due to systemic toxicity. It has been found that the full 
potential of TNF-α could be exploited while systemic 
distribution of TNF-α was prevented by local treat-
ment  protocols  such  as  isolated  limb  perfusion 
[70-71]. Thus, specific targeting of TNF-α to a selective 
cell population may improve its cytostatic potential. 
One example is the conjugate of RGD peptide with the 
TNF mutant V29, where Arginine 29 was replaced by 
Valine. TNF-V29 selectively binds to TNF-R1 rather 
than TNF-R2 [72], and TNF-V29 showed potent anti-
tumor activity in mice, combined with a reduced sys-
temic toxicity [73]. In addition, it has been reported 
that RGD-motif in wild-type TNF reduced its gastro-
intestinal  toxicity  [74]  and  improved  its  an-
ti-metastatic  activity  [75].  Thus,  the  RGD-TNF-V29 
mutant F4614 was expected to achieve better overall 
therapeutic  efficacy  as  compared  to  the  RGD  and 
wild-type  TNF  conjugate.  Indeed,  RGD-TNF-V29 
displayed considerably lower cytotoxicity in normal 
endothelial  cells,  while  culturing  in  tu-
mor-conditioned  medium  restored  the 
TNF-responsiveness of endothelial cells to the level of 
wild type TNF-α [76]. RGD-TNF-V29 also showed an 
increased tumor selectivity of up to 460-fold, whereas 
wild-type TNF displayed only a 4-fold difference in 
tumor-endothelial  selectivity.  In  in  vivo  studies, 
RGD-TNF-V29  demonstrated  a  2-fold  improved 
therapeutic index (LD50/MED = 4.8), which may be 
contributed  by  the  improved  accumulation  in  the 
tumor  tissue  [73].  In  another  example  [77],  RGD4C 
peptide was conjugated with a TNF-α fusion protein, 
mouse-TNF-α (mTNF-α). Because mTNF is a compact 
homotrimeric protein, RGD4C-TNF actually contains 
three binding domains per protein. Due to this mul-
tivalent effect, RGD4C-TNF showed a 10-fold higher 
affinity than free RGD4C peptide for integrin αvβ3 in 
the endothelial cell line EA.hy926. It was also found 
that subnanogram doses of RGD4C-TNF are sufficient 
to induce antitumor effects in tumor-bearing mice as 
combined with melphalan, a chemotherapeutic drug. 
Cell  adhesion  assays  and  competitive  binding  ex-
periments  with  anti-integrin  antibodies  further 
demonstrated that showed that the RGD moiety in-
teracts with integrin αvβ3. In addition, RGD4C-TNF 
conjugate induced cytotoxic effects in standard cyto-
lytic assays, implying that RGD4C-TNF conjugate can 
also  bind  TNF  receptors  and  trigger  death  signals. 
These  results  suggested  that  coupling  TNF  with 
RGD4C improves its anti-neoplastic activity. We re-
cently developed an RGD4C-TNF fusion protein for 
tumor-specific delivery of TNF [78-79]. RGD4C-TNF 
was significantly more potent than TNF in inhibiting 
orthotopic MDA-MB-435 tumor growth. Intramuscu-
lar  administration  of  plasmid  DNA  encoding 
RGD4C-TNF also was found to inhibit the growth of 
melanomas and lymphomas implanted at sites distant 
from the plasmid injection site [80]. Tumor necrosis 
factor  (TNF)-related  apoptosis  inducing  ligand 
(TRAIL) is an apoptosis-inducing member of the TNF 
gene family, which acts as a homotrimer interacting 
with  five  cognate  receptors:  TRAIL-R1,  TRAIL-R2, 
TRAIL-R3,  TRAIL-R4,  and  osteoprotegerin  (OPG). 
Unlike  the  other  TNF  family  members  TNF-α  and 
CD95L, TRAIL has the unique ability to elicit apop-
totic cell death in a variety of cancer cells, with mini-
mal cytoxicity for normal cells and tissues. The con-
jugate  of  the  fusion  of  TRAIL  with  the  RGD-based 
peptide has been reported  [81]. The results showed 
that RGD4C led to enhanced apoptosis inducing ac-
tivity (caspase-3 and caspase-8 activation) in integrin 




Tissue Factor (TF) is a cell membrane receptor 
protein that is the initiator of the extrinsic pathway of 
the blood coagulation cascade and normally released 
from  damaged  tissues  [82].  It  is  expected  that  this 
potent  thrombogenic  protein  in  its  truncated  form 
(tTF)  can  be  targeted  to  the  tumor,  occlude  the  tu-
mor’s blood supply and, thus cause rapid tumor de-
struction.  To  test  this  hypothesis,  three  fusion  pro-
teins,  chTNT-3/tTF,  chTV-1/tTF,  and  RGD/tTF, 
which target DNA exposed in degenerative areas of 
tumors, fibronectin on the tumor vascular basement 
membrane, and integrin αvβ3 on the luminal side of 
tumor  vessels,  respectively,  were  developed  and 
tested for their antitumor effects [82]. In vitro, all fu-
sion proteins retained similar thrombotic activity. In 
MAD109  mouse  lung  tumor  model,  RGD-tTF  was 
found to be localized mainly in capillaries and small 
vessels  of  the  tumor.  In  vivo,  daily  injections  of 
RGD-tTF resulted in thrombosis of about 40% of the 
tumor blood vessels, but no significant inhibition of 
tumor  growth  was  observed.  In  contrast,  the  other 
two fusion proteins showed thrombosis in up to 80% 
of the scored blood vessels, leading to massive tumor 
necrosis  and  more  than  50%  reduction  in  tumor 
volume  versus  the  RGD-tTF  group.  Similar  results 
were obtained in the C26 colon carcinoma model. The 
data implied that these thrombogenic agents had to 
occlude medium and large vessels within the tumor in 
order to attain a significant antitumor effect. Interest-
ingly,  most  impressive  tumor  suppression  was  ob-
served for the combination therapy of all three-fusion 
proteins, suggesting the delivery of tTF to all available 
targets produced an additive thrombotic effect.  
Interleukin 12 (IL-12) plays an important role in 
the activities of natural killer (NK) cells and T lym-
phocytes.  It  mediates  enhancement  of  the  cytotoxic 
activity of  NK cells and CD8+  cytotoxic T lympho-
cytes. However, systemic administration of IL-12 was 
associated with dose-limiting toxicity, thus prevent-
ing IL-12 from attaining its full therapeutic potential 
[83]. A fusion protein was synthesized by conjugating 
mouse  IL-12  with  RGD4C  [84].  The  results  showed 
that  RGD4C-IL-12  retained  the  immunostimulatory 
activity  of  IL-12.  In  corneal  angiogenesis  assay, 
RGD4C-IL-12  demonstrated  excellent  inhibition  of 
bFGF-induced vessel growth, whereas native mIL-12 
only  partially  inhibited  neovascularization.  In  addi-
tion,  in  a  neuroblastoma  model  (NXS2  model), 
RGD4C-IL-12 showed an improved antitumor effect, 
whereas  native  IL-12  was  not  effective.  Moreover, 
RGD4C-mediated targeting prevented IL-12 induced 
hepatic necrosis, which was observed after continu-
ous subcutaneous infusion for two weeks via surgi-
cally  implanted  osmotic  pumps.  While  RGD-IL-12 
was tested in knockout mice lacking the IL-12 recep-
tor, RGD4C-IL-12 showed the neovascularization in-
hibition  for  up  to  25%,  whereas  mIL-12  was  com-
pletely ineffective. The enhanced antiangiogenic effect 
of  mrIL-12vp  may  involve  several  mechanisms,  in-
cluding increased IL-12 concentrations delivered di-
rectly  to  angiogenic  endothelial  cells,  activation  of 
immune cells within the angiogenic site, and contri-
bution of RGD4C in suppressing endothelial cell sur-
vival pathways.  
The  various  conjugates  of  RGD-peptides  and 
therapeutic  peptides  and  proteins  
[67,69,73,77-78,80-82,84-88] are summarized in Table 
2. 
Table 2 Integrin targeted delivery of therapeutic peptides and proteins 
Therapeutic agent  Targeting motif  Experimental model  Resultsa  Ref. 
In Vitro  In Vivo 
(KLAKLAK)2  RGD4C  MDA-MB-435 mammary carcinoma  +  +  [67] 
Tachyplesin  CRGDC  TSU prostate cancer cell lines and B16 melanoma  +  +  [69] 
Truncated tissue factor (tTF)  RGD4C  MAD109 and COLON 26  +  +  [82] 
mIL12  RGD4C  NXS2 neuroblastoma  –  +  [84] 
Endostatin   RGDS  LS174T colon carcinoma  +  +  [85] 
Fc fragment of IgG  RGD4C  DU145 prostate carcinoma  ND  +  [86] 
Hu-TNFα  RGD4C  B16F1 melanoma  ND  +  [80] 
Hu-TNFα mutant selective for TNFR1 
(V29)  
RGDSD  Meth A fibrosarcoma and Mqnu-1 lung cancer   –  +  [73] 
mTNFα  RGD4C  RMA  =  +  [77] 
TNF  RGD4C  MDA-MB-435  =  +  [78] 
Anti-CD3-mAB  c(RGDfK)  HUVEC  +  ND  [88] 
TRAIL  c(RGDfK)-PEG  Jurkat T cells and HUVEC  =  ND  [87] 
TRAIL  RGD  COLO-205 and HT-29 human colon carcinoma  +  +  [81] 
a Efficacy compared to non-targeted chemotherapeutic agent: Improved efficacy (+), comparable efficacy (=), less efficacy (–), and not de-
termined (ND). 




Integrin targeted delivery of nanoparti-
cle-carried chemotherapeutic agents 
The  third  approach  is  to  employ  a  nanoparti-
cle-carried delivery system. Integrin targeted ligands, 
such as RGD peptides, can be coated on the surface of 
nanoparticle  carrier  system  to  selectively  deliver 
chemotherapeutic agents to cancer cells or diseased 
tissues.  There  are  several  advantages  for  the  nano-
particle carrier system over conventional drug deliv-
ery  system.  First,  multivalent  ligands  can  be  conju-
gated on the surface of the nanoparticle. Multivalency 
not only significantly improves the binding affinity to 
the integrin, but also facilitates internalization. Carrier 
systems,  such  as  liposomes  and  nanoparticles,  after 
bearing multiple RGD-peptides, can be more readily 
internalized via receptor-mediated endocytosis. As a 
result, larger amount of chemotherapeutic agents can 
be delivered through internalizing receptor-targeted 
ligand. In addition, high molecular weight of nano-
particle  carriers  may  lead  to  passive  retention  in  a 
tumor.  Leaky  blood  vessels  and  poor  lymphatic 
drainage  are  commonly  presented  in  tumor.  Nano-
particles can penetrate and accumulate in the tumor 
via those leaky vessels by the enhanced penetration 
and  retention  (EPR)  effect  [89].  In  order  to  protect 
nanoparticles  from  protein  absorption  and  prolong 
the circulation time after administration, polyethylene 
glycol (PEG) is normally incorporated into the deliv-
ery system. The most commonly used nanoparticulate 
delivery systems include liposomes, polymeric nan-
osphere, micelles, and polymersomes [90].     
The  RGD-containing  peptide-decorated  nano-
particulate delivery system has been extensively in-
vestigated. For example, RGD-peptides were coupled 
to the distal end of poly(ethylene glycol)-coated lipo-
somes (LCL) to obtain a stable long-circulating drug 
delivery system functioning as a platform for multi-
valent interaction with integrin αvβ3 [91]. The results 
showed  that  RGD-peptide-modified  LCL  exhibited 
increased binding to endothelial cells in vitro. More-
over,  intravital  microscopy  demonstrated  a  specific 
interaction  of  these  liposomes  with  tumor  vascula-
ture, a characteristic not observed for LCL. In in vivo 
study, RGD–LCL encapsulating doxorubicin inhibited 
tumor  growth  in  a  doxorubicin-insensitive  murine 
C26 colon carcinoma model, whereas doxorubicin in 
LCL  failed  to  decelerate  tumor  growth.  Overall, 
RGD–LCL  containing  doxorubicin  showed  superior 
efficacy  over  non-targeted  LCL  in  inhibiting  C26 
doxorubicin-insensitive  tumor  outgrowth.  Likely, 
these  RGD–LCL–doxorubicin  antitumor  effects  are 
brought about through direct effects on tumor endo-
thelial cells [91]. Recently, cRGDfK peptide was cou-
pled to PEGylated liposome encapsulating anticancer 
drug (doxorubicin) to target integrin αvβ3-expressing 
tumor vasculature [92]. The results showed that de-
livery of targeted nanoparticles inhibited the growth 
of  metastases  while  eliminating  the  toxicity  and 
weight loss associated with systemic administration 
of doxorubicin. The delivery resulted in a 15-fold im-
provement in tumor and anti-metastatic activity when 
compared with administration of the free drug. The 
preferential activity of these nanoparticles on metas-
tases  implies  that  growing  metastatic  tumors  may 
have a greater dependence on angiogenic vessels and 
thus  could  be  more  susceptible  to  integrin 
αvβ3-targeted  therapy  [93].  In  another  example, 
Xiong et al. achieved high tumor accumulation and 
intercellular delivery of doxorubicin after conjugating 
synthetic  RGD  mimic  compound  with  the 
drug-loading  liposome  in  syngeneic  B16  melanoma 
mouse  model.  Administration  of  RGD  mim-
ic-modified nanoparticle resulted in retarded tumor 
growth  and  prolonged  lifespan  compared  with  the 
non-modified  one  [94-95].  Similar  RGD  liposome 
modification strategies have also been used to deliver 
other anticancer drugs, such as 5-fluorouracil (5-FU) 
and paclitaxel, to malignant tumor-bearing animals. 
The significant anti-primary tumor and antimetastatic 
activities can also be achieved [96, 52, 97]. The lipo-
somal  delivery  of  a  new  snake  venom  disintegrin, 
contortrostatin (CN) has been reported in an ortho-
topic human breast tumor xenograft model [98]. This 
disintegrin modulates its interaction with integrins on 
tumor cells and angiogenic vascular endothelial cells.  
RGD-modified liposomes have also been applied 
for  other  disease  treatments  in  addition  to  cancer 
therapy.  The  effect  of  RGD-modified  liposomes  on 
platelet activation and aggregation was investigated 
in  vitro,  with  and  without  platelet  agonists  [99]. 
RGD-liposomes were found to bind activated plate-
lets  at  levels  significantly  greater  than  the  control 
RGE-liposomes. The RGD-liposomes did not exhibit 
any statistically significant effect on platelet activation 
or aggregation. The results demonstrate the ability of 
the RGD-modified liposomes to target and bind acti-
vated  platelets  without  causing  significant  platelet 
aggregation and suggests a feasible way for the de-
velopment  of  a  platelet-targeted  anti-thrombogenic 
drug delivery system. In another study, RGD-coated 
liposomes were developed for selective cell targeting 
in cardiovascular drug delivery [100].  
Except for using liposome as a carried system, 
biodegradable  polymeric  micelles,  a  type  of 
self-assembled  nanoparticle  from  amphiphilic  co-
polymers, were utilized as a carrier system for integ-




showed  that  attachment  of  the  cyclic  RGD  ligand 
greatly  enhanced  internalization  of  the  micelles  in 
tumor  endothelial  cells  that  overexpress  integrin 
αvβ3,  apparently  through  receptor-mediated  endo-
cytosis. Biodegradable nanosphere is another attrac-
tive  carrier  system  for  drug  delivery.  A 
RGD-PEG-PLGA  nanosphere  delivery  system  was 
developed for intracellular delivery of doxorubicin to 
different  malignant  cancer  cells  [102].  The  results 
showed this new nanosphere can alleviate the burst 
drug release effect commonly associated with PLGA 
nanosphere systems. Recently, self-assembled glycol 
chitosan  nanoparticles  were  developed  to  explore 
whether this construct might function as a prolonged 
and sustained drug delivery system for RGD peptide 
[103]. In vitro work demonstrated that RGD-HGC can 
prolong  and  sustain  release  of  RGD,  lasting  for  1 
week. RGD-HGC also inhibited HUVEC adhesion to a 
beta ig-h3 protein-coated surface, indicating an anti-
angiogenic effect of the RGD peptide in the HGC na-
noparticles.  In  an  in  vivo  study,  the  antiangiogenic 
peptide  drug  formulation  of  RGD-HGC  markedly 
inhibited bFGF-induced angiogenesis and decreased 
hemoglobin content  in Matrigel plugs. Intratumoral 
administration of RGD-HGC significantly decreased 
tumor growth and microvessel density compared to 
native RGD peptide. 
The  various  conjugates  of  RGD-peptides  and 
nanoparticle-carried  chemotherapeutic  agents 
[52,91-92,94-96,104-105]  are summarized in Table 3. 
 
Table 3 Integrin targeted delivery of nanoparticle-carried chemotherapeutic agents 
Nanocarriers   Therapeutic agent  Targeting motif  Experimental model  Resultsa  Ref. 
In Vitro  In Vivo 
Liposome   Doxorubicin  c(RGDfK)-PEG  C26 murine colon carcinoma  ND  +  [91] 
Liposome   Doxorubicin  RGD10  C26 murine colon carcinoma  ND  +  [52] 
Liposome   Doxorubicin  RGD-PEG  B16 murine melanoma  –  +  [94,95] 
Nanoparticle   Doxorubicin  c(RGDfC)-PEG  Cl-66 mammary carcinoma  ND  ND  [104] 
Liposome  Doxorubicin  c(RGDfK)-PEG  Orthotopic mouse R40P 
pancreatic carcinoma, hu-
man M21L-GFP melanoma, 
and human SN12C-RFP 
renal carcinoma  
+  +  [92] 
Liposome   5-Fluorouracil  c(RGDfK)-PEG  B16F10 murine melanoma  +  +  [96] 
Nanoparticle  Fumagillin  Intergrin αvβ3 pep-
tidomimetic antago-
nist 
Vx-2 rabbit adenocarcinoma  ND  +  [105] 




Development  of  molecular  devices  endowed 
with  disease-targeting  functions  and  carrying  cyto-
toxic  components  enables  the  specific  delivery  of 
chemotherapeutic agents to aberrant tissues, thus in-
creasing  their  local  efficacy  while  limiting  their  pe-
ripheral toxicity. A large number of studies demon-
strated  that  integrin  receptor,  in  particular  integrin 
αvβ3, is an ideal target of specific delivery of chemo-
therapeutic  agents,  because  not  only  integrin  αvβ3 
can  be  internalized  by  cells  on  activation  with  an-
choring  ligands,  but  also  integrin  αvβ3  is  overex-
pressed on angiogenetic endothelial cells and absent 
in  pre-existing  endothelial  cells  and  normal  tissues. 
Therefore, integrin targeted delivery of chemothera-
peutic agents represents a valuable approach and the 
numerous  results  obtained  to  date  using  different 
systems open up interesting prospect to future chem-
otherapy in treatment of various diseases. 
Approaches  based  on  multivalent  presentation 
of the RGD ligand will likely continue to receive at-
tention in the future since they provide therapeutic 
agents  with  higher  binding  affinity,  prolonged 
half-life, and passive retention in diseased tissues and 
are compulsory for cellular uptake. In this regard, the 
employment of nanoparticle will certainly represents 
a  promising  area  of  continuing  investigation.  How-
ever, the toxicity of  novel nanoparticle carriers will 
have to be clearly addressed in future clinical appli-
cation. In addition, since integrin αvβ3 expression is 
not homogeneous all over diseased tissues, strategies 
that combine multiple biomarkers, such as vascular 
endothelial growth factor (VEGF), fibroblast growth 
factor  (FGF),  epidermal  growth  factor  (EGF),  and 
other integrin receptors are expected to generate sig-
nificantly  greater  benefits  for  optimal  treatment. 
Moreover, in order to maximize the therapeutic index, 
therapeutic  multi-modalities,  the  combination  of 
chemotherapy, radiotherapy, and gene therapy, will 
be likely  more effective than single modality alone. 
However, the specific synergistic interactions among 
different  modalities  have  to  be  investigated  and 
clearly  understood.  Finally,  non-invasive  imaging 




logical processes of disease at the cellular and molec-
ular level in real time. Thus, imaging-guided therapy 
should be routinely applied in clinical settings to im-
prove  the  overall  patient  outcome  and  help  further 
steps toward personalized medicine. 
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